이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Pharmena 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Konrad Palka

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	8.9%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3.5yrs

최근 관리 업데이트

Recent updates

We Think Pharmena's (WSE:PHR) Solid Earnings Are Understated

Jun 04

Pharmena's (WSE:PHR) Solid Earnings Are Supported By Other Strong Factors

Dec 04

CEO 보상 분석

Konrad Palka 의 보수는 Pharmena 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	zł29m
Mar 31 2024	n/a	n/a	zł29m
Dec 31 2023	n/a	n/a	zł27m
Sep 30 2023	n/a	n/a	zł29m
Jun 30 2023	n/a	n/a	-zł7m
Mar 31 2023	n/a	n/a	-zł6m
Dec 31 2022	zł300k	zł300k	-zł5m

보상 대 시장: Polish 시장에서 비슷한 규모의 회사에 비해 Konrad 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Konrad 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Konrad Palka

no data

테뉴어

zł300,000

보상

Mr. Konrad Palka serves as President of the Management Board, Chief Executive Officer and President at Pharmena Spolka Akcyjna. Prior to joining Pharmena, Mr. Palka worked in the financial sector. From 199...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jacek Szwajcowski	Member of Supervisory Board	no data	데이터 없음	데이터 없음
Brian Halak	Member of Strategic Advisory Board	no data	데이터 없음	데이터 없음
Eugenio Cefali	Member of Strategic Advisory Board	no data	데이터 없음	데이터 없음
Dennis Giesing	Member of Strategic Advisory Board	no data	데이터 없음	데이터 없음
Jacek Dauenhauer	Member of the Supervisory Board	no data	데이터 없음	0.028% PLN 17.8k
Zbiegniew Molenda	Member of Supervisory Board	no data	데이터 없음	데이터 없음
Agnieszka Dziki	Independent Member of the Supervisory Board	5.3yrs	데이터 없음	데이터 없음
Anna Janicka	Member of Supervisory Board	3.5yrs	데이터 없음	데이터 없음
Tomasz Filipiak	Chairman of the Supervisory Board	less than a year	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 이사회: PHR 의 이사회는 경험(평균 재직 기간 3.4 년)으로 간주됩니다.

Pharmena 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Pharmena S.A., Annual General Meeting, Apr 03, 2024

Pharmena S.A., Annual General Meeting, Jun 13, 2023

Pharmena S.A., Annual General Meeting, Jun 28, 2022

Recent updates

Second quarter 2024 earnings released: zł0.081 loss per share (vs zł0.051 loss in 2Q 2023)

We Think Pharmena's (WSE:PHR) Solid Earnings Are Understated

First quarter 2024 earnings released: EPS: zł0.021 (vs zł0.014 loss in 1Q 2023)

Investor sentiment deteriorates as stock falls 19%

Upcoming dividend of zł0.85 per share

New minor risk - Dividend sustainability

Pharmena S.A., Annual General Meeting, Apr 03, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 18%

Pharmena S.A. to Report Q3, 2024 Results on Nov 27, 2024

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 20%

Pharmena's (WSE:PHR) Solid Earnings Are Supported By Other Strong Factors

Third quarter 2023 earnings released: EPS: zł2.70 (vs zł0.01 loss in 3Q 2022)

Pharmena S.A., Annual General Meeting, Jun 13, 2023

Pharmena S.A. to Report Q1, 2023 Results on May 26, 2023

Third quarter 2022 earnings released: zł0.01 loss per share (vs zł0.053 loss in 3Q 2021)

Second quarter 2022 earnings released: zł0.041 loss per share (vs zł0.17 loss in 2Q 2021)

First quarter 2022 earnings released: zł0.015 loss per share (vs zł0.052 loss in 1Q 2021)

Pharmena S.A., Annual General Meeting, Jun 28, 2022

Pharmena S.A. to Report Q3, 2022 Results on Nov 25, 2022

Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint

First quarter 2021 earnings released: zł0.052 loss per share (vs zł0.069 loss in 1Q 2020)

Full year 2020 earnings released: zł0.63 loss per share (vs zł0.94 loss in FY 2019)

Pharmena S.A. to Report First Half, 2021 Results on Aug 27, 2021

New 90-day low: zł8.94

Third quarter 2020 earnings released: zł0.068 loss per share

New 90-day low: zł9.20

Pharmena S.A. announced that it expects to receive PLN 1.5 million in funding

New 90-day low - zł11.65

First half earnings released

New 90-day high - zł18.60

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령